fashion -WSS

fashion

author：explore 2025-10-01 02:27:24 - browse：39928

An Ozempic pen connects dots that make up the shape o a brain — coverage from STAT — ILLUSTRATION: CHRISTINE KAO/STAT; PHOTOS: ADOBE

Drugs like Ozempic and Wegovy — already game changers for diabetes and obesity — are being studied to treat an entirely different growing health problem: mental health illnesses, including depression and bipolar disorder.

Early data and anecdotes suggest that this class of GLP-1 drugs could help patients feel less depressed and anxious. The treatment may also fight the decline in cognitive and executive function that many people with mental health disorders experience, like worsening memory and losing the ability to focus and plan.

If further research yields positive results, it could drive even more demand for the highly popular GLP-1 treatments, which have increasingly been shown to help with problems across the body, such as heart and kidney complications. And especially if the cognitive benefits are proven out, the GLP-1 drugs would plug a critical gap in current treatments for depression, since most depression drugs help with mood, but close to none address cognitive symptoms that affect memory and attention.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Readout LOUD podcast: ALS dilemma, first MASH drug, and more

leisure time

WSS

Virtual repurposing can help discover new uses for existing drugs

Cholera vaccine supplies dangerously low, outbreaks surging

First U.S. drug developed to treat liver disease MASH is approved

President Biden's budget: Here's what you might have missed

Pushing for an NIH office for post

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

entertainment

fashion

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Laying a path for careers in science

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

How to save PrEP access — and even expand it

Redefining sustainability for the pharmaceutical industry

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why depression after traumatic brain injury is distinct

focus

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Change Healthcare outage fallout shows need for new oversight

Readout Newsletter: Beam, Prozac, "TechBio" and more

FDA advisers back CAR

HHS secretary Becerra pressed on Change HealthCare cyberattack

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

leisure time

leisure time

hotspot

focus